Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2013 | 02:26pm CEST

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
09/21 ASTRAZENECA : Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
09/21 ASTRAZENECA : New Toxicology Findings from AstraZeneca Described (An Analysis of..
09/21 IONIS PHARMACEUTICALS : New Data Presented at European Society for Medical Oncol..
09/19 Recipharm to make clinical trial cancer candidate for Kancera
09/19 ASTRAZENECA : Aspen to acquire remaining rights to AstraZenecas anaesthetic medi..
09/18 ASPEN PHARMACARE : Hits & Misses. Hits. Tshabalala leads Standard alone but SA b..
09/18 ASTRAZENECA : asthma drug does well in late stage trials
09/16 Aspen Pharmacare posts 46% profit jump
09/16 ASTRAZENECA : Antidote Industry Growth in Global Countries (United States, China..
09/15 ASTRAZENECA : selling off remainder of anesthetic medicine holdings
More news
News from SeekingAlpha
09/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
09/22 Premarket analyst action - healthcare
09/21 Mirati Brings Hope With Its Stellar Performance
09/18 YOUR DAILY PHARMA SCOOP : ACADIA's Growth Potential, Lexicon's Diabetes Troubles..
09/14 CV risk of AstraZeneca's Bydureon on par with placebo in large-scale study
Financials ($)
Sales 2017 21 551 M
EBIT 2017 5 774 M
Net income 2017 2 586 M
Debt 2017 12 314 M
Yield 2017 4,21%
P/E ratio 2017 29,01
P/E ratio 2018 24,89
EV / Sales 2017 4,35x
EV / Sales 2018 4,30x
Capitalization 81 444 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 65,5 $
Spread / Average Target 1,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA7.46%81 444
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914